Non-inferiority Study of Safety and Efficacy of Everolimus With Low Dose Tacrolimus to Mycophenolate Mofetil With Standard Dose Tacrolimus in Kidney Transplant Recipients

Official title

A 12 Month, Multi-center, Randomized, Open-label Non-inferiority Study Comparing Safety and Efficacy of Concentration-controlled Everolimus With Low Dose Tacrolimus to Mycophenolate Mofetil With Standard Dose Tacrolimus in de Novo Renal Transplant Recipients

Study identification

NCT ID

NCT01025817

Recruitment status

Completed

Study type

Interventional

Phase

Phase 3

Lead sponsor

Novartis Pharmaceuticals

Industry

Enrollment

613 participants

Conditions and interventions

Eligibility (public fields only)

Age range

18 Years to 70 Years

Sex

All

Healthy volunteers

Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date

Jan 2010 (Type not available)

Primary completion

Mar 2013 (Actual)

Completion

Mar 2013 (Actual)

Last update posted

Nov 11, 2015

2010 – 2013

United States locations

U.S. sites

48

U.S. states

24

U.S. cities

42

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.